Next Article in Journal
Lights and Shadows in Immuno-Oncology Drug Development
Next Article in Special Issue
Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor
Previous Article in Journal
Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Why Target Innate Immune Cells in Cancers?

by 1,2
Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, 31037 Toulouse, France
Université Toulouse III Paul-Sabatier, 31400 Toulouse, France 3. ERL 5294 CNRS, 31037 Toulouse, France
Cancers 2021, 13(4), 690;
Received: 28 January 2021 / Accepted: 5 February 2021 / Published: 9 February 2021
(This article belongs to the Special Issue Targeting the Innate Immune Cells in Cancers)
Note: In lieu of an abstract, this is an excerpt from the first page.

The immune system is a smart way to fight cancer, with its precise targeting of cancer cells sparing healthy cells [...] View Full-Text
MDPI and ACS Style

Poupot, M. Why Target Innate Immune Cells in Cancers? Cancers 2021, 13, 690.

AMA Style

Poupot M. Why Target Innate Immune Cells in Cancers? Cancers. 2021; 13(4):690.

Chicago/Turabian Style

Poupot, Mary. 2021. "Why Target Innate Immune Cells in Cancers?" Cancers 13, no. 4: 690.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop